Table 3 BRCA pathway aberrations and clinicopathological features.
Features | BRCA pathway genes | P | BRCA2 expression | P | ||
|---|---|---|---|---|---|---|
Potentially deleterious mutations* | Wild type or benign mutations** | Retain | Reduced | |||
BRCA2 mutation | ||||||
Mutant | 8 | 2 | — | 8 | 2 | 1.00 |
Wild | 1 | 31 | — | 27 | 5 | |
Age at operation | ||||||
Mean (range) | 68 (53–79) | 65 (43–87) | 0.40 | 65 (43–87) | 70 (56–77) | 0.23 |
T*** | ||||||
T1, T2 | 3 | 9 | 0.70 | 10 | 2 | 1.00 |
T3, T4 | 6 | 24 | 25 | 5 | ||
N*** | ||||||
N0 | 1 | 12 | 0.23 | 11 | 2 | 1.00 |
N1, N2 | 8 | 21 | 24 | 5 | ||
Stage*** | ||||||
0 | 0 | 0 | 0.44 | 0 | 0 | 0.52 |
I | 0 | 1 | 1 | 0 | ||
II | 0 | 6 | 5 | 1 | ||
III | 6 | 12 | 13 | 5 | ||
IVa | 3 | 13 | 15 | 1 | ||
IVb | 0 | 1 | 1 | 0 | ||
Histology | 0 | 0 | 0.44 | |||
Tubular adenocarcinoma | 8 | 27 | 1.00 | 30 | 5 | 0.58 |
other | 1 | 6 | 5 | 2 | ||
Recurrence | ||||||
Yes | 4 | 23 | 0.24 | 23 | 4 | 0.69 |
No | 5 | 10 | 12 | 3 | ||
Previous cancer history | ||||||
Yes | 1 | 10 | 0.40 | 10 | 1 | 0.65 |
No | 8 | 23 | 25 | 6 | ||
Family history of any cancers | ||||||
Yes | 3 | 18 | 0.45 | 17 | 4 | 1.00 |
No | 6 | 15 | 18 | 3 | ||
Family history of pancreatic cancer | ||||||
Yes | 0 | 5 | 0.57 | 4 | 1 | 1.00 |
No | 9 | 28 | 31 | 6 | ||
Prognosis | ||||||
5-year overall survival | 68.6% | 19.2% | 0.031 | 34.3% | 0% | 0.83 |
